NEWTON, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) — Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced that the Company will present updated preclinical data from its lead program during a poster session at the 31st Annual Prostate Cancer Foundation (PCF) Annual Scientific Retreat from October 24-26, 2024 in Carlsbad, CA.
At PCF, Auron will present in vitro and in vivo data from AUTX-703, its oral, potent and selective degrader of KAT2A/B that is being developed for the treatment of AML and neuroendocrine carcinomas including SCLC and NEPC. Auron is on-track to submit an Investigational New Drug (IND) application for AUTX-703 in late 2024 for initiation of clinical development in early 2025.
Details for Auron’s presentation at the PCF Annual Scientific Retreat are below:
- Abstract Title: AUTX-703, a Highly Potent and selective KAT2A and KAT2B Protein Degrader, Induces Cell State Changes and Inhibits Growth in NEPC and SCLC Cancers
- Session Date and Time: Thursday, October 24, 7:30 – 10:30 p.m. PT
About Auron Therapeutics
Auron Therapeutics is a patient-centered, platform-powered, product-driven oncology company. Auron is leading the next generation of targeted cancer therapies by identifying and inhibiting the oncogenic cell states of cancer. Auron pioneered its AURIGIN
Investor Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow